170 related articles for article (PubMed ID: 23371259)
1. [Chronic lymphocytic leukemia. Treatment and genetic risk profile].
Stilgenbauer S; Hallek M
Internist (Berl); 2013 Feb; 54(2):164, 166-70. PubMed ID: 23371259
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
3. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
4. [Chronic lymphocytic leukemia : treatment concepts in transition].
Eichhorst B; Hallek M
Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
[TBL] [Abstract][Full Text] [Related]
5. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
8. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
Cramer P; Hallek M; Eichhorst B
Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
[TBL] [Abstract][Full Text] [Related]
11. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
13. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
14. [Chronic lymphocytic leukemia: update on pathophysiology and management].
Suzumiya J
Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
[TBL] [Abstract][Full Text] [Related]
15. [Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Schlenk RF; Döhner K; Döhner H
Internist (Berl); 2013 Feb; 54(2):171-8. PubMed ID: 23358744
[TBL] [Abstract][Full Text] [Related]
16. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
17. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
18. Precision Medicine Management of Chronic Lymphocytic Leukemia.
Moia R; Patriarca A; Schipani M; Ferri V; Favini C; Sagiraju S; Al Essa W; Gaidano G
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164276
[TBL] [Abstract][Full Text] [Related]
19. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
Tausch E; Mertens D; Stilgenbauer S
Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
[TBL] [Abstract][Full Text] [Related]
20. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]